Status:
COMPLETED
Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious
Lead Sponsor:
Zekai Tahir Burak Women's Health Research and Education Hospital
Conditions:
Ductus Arteriosus, Patent
Eligibility:
All Genders
2+ years
Brief Summary
Patent ductus arterious(PDA)is frequently seen and potentially pathologic in preterm infants. Near-infrared spectroscopy is a simple bedside tool to analyse the changes in the renal and splanchnic tis...
Detailed Description
Patent ductus arterious (PDA) is the most common cardiovascular abnormality in preterm infants.There are clear associations between a PDA and decreased renal and splanchnic blood flow. The aim is to m...
Eligibility Criteria
Inclusion
- Gestational age \<32 weeks and \<1500 g
- Echocardiographic evidence of hemodynamically significant patent ductus arterious
Exclusion
- Major congenital anomalies
- Intraventricular hemorrhage of grade 3 within the previous 24 hours
- Serum creatinine level 1.5 mg%,serum urea nitrogen concentration \>50 mg%,
- Platelet count 60 000/mL3, a tendency to bleed (defined by the presence of hematuria, blood in the endotracheal aspirate, gastric aspirate, or stools and/or oozing from puncture sites)
- Hyperbilirubinemia necessitating exchange transfusion
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01251939
Start Date
October 1 2011
End Date
August 1 2012
Last Update
August 21 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zekai Tahir Burak Maternity and Teaching Hospital
Ankara, Turkey (Türkiye)